Glaukos Corporation (GKOS)
NYSE: GKOS · Real-Time Price · USD
125.88
-31.48 (-20.01%)
At close: Feb 21, 2025, 4:00 PM
126.30
+0.42 (0.33%)
After-hours: Feb 21, 2025, 4:43 PM EST
Glaukos Revenue
In the year 2024, Glaukos had annual revenue of $383.48M with 21.85% growth. Glaukos had revenue of $105.50M in the quarter ending December 31, 2024, with 28.09% growth.
Revenue (ttm)
$383.48M
Revenue Growth
+21.85%
P/S Ratio
17.32
Revenue / Employee
$422,802
Employees
907
Market Cap
6.94B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 383.48M | 68.77M | 21.85% |
Dec 31, 2023 | 314.71M | 31.85M | 11.26% |
Dec 31, 2022 | 282.86M | -11.15M | -3.79% |
Dec 31, 2021 | 294.01M | 69.05M | 30.70% |
Dec 31, 2020 | 224.96M | -12.03M | -5.07% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
GKOS News
- 1 day ago - Glaukos Delivers Mixed Q4 Results, Analyst Sees Growing Investor Interest During Transition - Benzinga
- 1 day ago - Glaukos Corporation (GKOS) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 1 day ago - Glaukos Announces Fourth Quarter and Full Year 2024 Financial Results - Business Wire
- 4 weeks ago - Glaukos to Release Fourth Quarter and Full Year 2024 Financial Results after Market Close on February 20 - Business Wire
- 5 weeks ago - Glaukos Announces Positive Clinical Updates for its iDose® Sustained-Release Procedural Pharmaceutical Platform - Business Wire
- 7 weeks ago - Glaukos To Rally Around 17%? Here Are 6 Top Analyst Forecasts For Tuesday - Benzinga
- 2 months ago - Glaukos Submits New Drug Application to U.S. FDA for Epioxa™ - Business Wire
- 2 months ago - Glaukos: Still Bullish, But Embedded Expectations Are Now High - Seeking Alpha